| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 99 | 2021 | 1014 | 6.960 |
Why?
|
| Percutaneous Coronary Intervention | 53 | 2021 | 467 | 5.690 |
Why?
|
| Registries | 104 | 2021 | 1884 | 5.310 |
Why?
|
| Cardiology | 31 | 2021 | 267 | 4.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 39 | 2014 | 138 | 3.850 |
Why?
|
| United States Department of Veterans Affairs | 40 | 2017 | 637 | 3.460 |
Why?
|
| Cardiovascular Diseases | 38 | 2021 | 2024 | 3.340 |
Why?
|
| Coronary Artery Disease | 26 | 2021 | 678 | 2.720 |
Why?
|
| Quality of Health Care | 31 | 2020 | 608 | 2.710 |
Why?
|
| Health Status | 35 | 2018 | 751 | 2.650 |
Why?
|
| Hospitals, Veterans | 17 | 2016 | 257 | 2.590 |
Why?
|
| Coronary Artery Bypass | 23 | 2017 | 222 | 2.420 |
Why?
|
| Quality Assurance, Health Care | 23 | 2015 | 317 | 2.280 |
Why?
|
| Coronary Disease | 15 | 2013 | 384 | 2.220 |
Why?
|
| Cardiac Catheterization | 21 | 2018 | 515 | 2.120 |
Why?
|
| United States | 175 | 2021 | 13940 | 2.080 |
Why?
|
| Transcatheter Aortic Valve Replacement | 18 | 2021 | 117 | 2.070 |
Why?
|
| Hospital Mortality | 45 | 2021 | 844 | 2.040 |
Why?
|
| Quality Indicators, Health Care | 20 | 2020 | 297 | 2.000 |
Why?
|
| Aged | 201 | 2021 | 22090 | 1.980 |
Why?
|
| Coronary Angiography | 20 | 2020 | 306 | 1.940 |
Why?
|
| Platelet Aggregation Inhibitors | 18 | 2018 | 440 | 1.920 |
Why?
|
| Heart Failure | 31 | 2016 | 2158 | 1.880 |
Why?
|
| American Heart Association | 28 | 2017 | 309 | 1.850 |
Why?
|
| Hospitals | 24 | 2017 | 632 | 1.790 |
Why?
|
| Quality of Life | 32 | 2018 | 2694 | 1.760 |
Why?
|
| Ticlopidine | 10 | 2016 | 54 | 1.750 |
Why?
|
| Depression | 20 | 2016 | 1293 | 1.630 |
Why?
|
| Aortic Valve Stenosis | 12 | 2021 | 218 | 1.610 |
Why?
|
| Acute Coronary Syndrome | 11 | 2017 | 267 | 1.580 |
Why?
|
| Angina Pectoris | 16 | 2016 | 67 | 1.570 |
Why?
|
| Myocardial Ischemia | 13 | 2016 | 249 | 1.470 |
Why?
|
| Humans | 332 | 2024 | 129128 | 1.440 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2016 | 413 | 1.420 |
Why?
|
| Angina, Unstable | 13 | 2016 | 77 | 1.400 |
Why?
|
| Practice Guidelines as Topic | 24 | 2021 | 1493 | 1.380 |
Why?
|
| Middle Aged | 163 | 2021 | 31080 | 1.360 |
Why?
|
| Treatment Outcome | 87 | 2021 | 10227 | 1.350 |
Why?
|
| Risk Assessment | 48 | 2021 | 3260 | 1.340 |
Why?
|
| Male | 220 | 2021 | 63202 | 1.310 |
Why?
|
| Product Surveillance, Postmarketing | 6 | 2015 | 60 | 1.300 |
Why?
|
| Aortic Valve | 10 | 2021 | 350 | 1.260 |
Why?
|
| Heart Valve Prosthesis Implantation | 7 | 2018 | 173 | 1.250 |
Why?
|
| Patient Selection | 16 | 2016 | 665 | 1.240 |
Why?
|
| Female | 217 | 2021 | 68518 | 1.240 |
Why?
|
| Guideline Adherence | 15 | 2017 | 525 | 1.210 |
Why?
|
| Hospitalization | 25 | 2016 | 2077 | 1.200 |
Why?
|
| Risk Factors | 86 | 2021 | 9769 | 1.190 |
Why?
|
| Atrial Fibrillation | 11 | 2021 | 379 | 1.170 |
Why?
|
| Telemedicine | 9 | 2021 | 783 | 1.160 |
Why?
|
| Cholesterol, LDL | 5 | 2015 | 361 | 1.140 |
Why?
|
| Patient Readmission | 13 | 2017 | 668 | 1.130 |
Why?
|
| Wearable Electronic Devices | 7 | 2024 | 43 | 1.100 |
Why?
|
| Drug-Eluting Stents | 11 | 2016 | 64 | 1.080 |
Why?
|
| Practice Patterns, Physicians' | 14 | 2018 | 1270 | 1.070 |
Why?
|
| Defibrillators, Implantable | 10 | 2015 | 295 | 1.060 |
Why?
|
| Veterans | 19 | 2016 | 1419 | 1.050 |
Why?
|
| Models, Statistical | 13 | 2019 | 626 | 1.030 |
Why?
|
| Biomedical Technology | 3 | 2018 | 40 | 1.020 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2011 | 319 | 1.010 |
Why?
|
| Multivariate Analysis | 32 | 2017 | 1496 | 0.970 |
Why?
|
| Aged, 80 and over | 62 | 2021 | 7066 | 0.940 |
Why?
|
| Electrocardiography | 20 | 2021 | 607 | 0.930 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2016 | 201 | 0.910 |
Why?
|
| Quality Improvement | 10 | 2020 | 1099 | 0.900 |
Why?
|
| Societies, Medical | 10 | 2020 | 749 | 0.900 |
Why?
|
| Data Mining | 4 | 2019 | 109 | 0.890 |
Why?
|
| Hypercholesterolemia | 2 | 2015 | 101 | 0.880 |
Why?
|
| Heart Valve Diseases | 5 | 2017 | 151 | 0.860 |
Why?
|
| Diffusion of Innovation | 3 | 2020 | 96 | 0.850 |
Why?
|
| Time Factors | 54 | 2019 | 6518 | 0.840 |
Why?
|
| Veterans Health | 5 | 2017 | 175 | 0.830 |
Why?
|
| Continuity of Patient Care | 4 | 2016 | 279 | 0.820 |
Why?
|
| Cohort Studies | 39 | 2021 | 5407 | 0.800 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2020 | 239 | 0.780 |
Why?
|
| Retrospective Studies | 62 | 2021 | 14571 | 0.770 |
Why?
|
| Angina, Stable | 3 | 2016 | 17 | 0.760 |
Why?
|
| Treatment Refusal | 5 | 2008 | 87 | 0.750 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2013 | 492 | 0.740 |
Why?
|
| Heart Rate | 4 | 2021 | 808 | 0.740 |
Why?
|
| Postoperative Complications | 16 | 2018 | 2496 | 0.740 |
Why?
|
| Mortality | 12 | 2017 | 308 | 0.730 |
Why?
|
| Acute Kidney Injury | 11 | 2019 | 774 | 0.720 |
Why?
|
| Cardiac Care Facilities | 2 | 2014 | 12 | 0.720 |
Why?
|
| Myocardial Revascularization | 7 | 2016 | 69 | 0.720 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2020 | 317 | 0.700 |
Why?
|
| Machine Learning | 4 | 2021 | 447 | 0.700 |
Why?
|
| Patient Discharge | 11 | 2017 | 857 | 0.690 |
Why?
|
| Follow-Up Studies | 38 | 2021 | 4915 | 0.690 |
Why?
|
| Ezetimibe | 2 | 2017 | 26 | 0.680 |
Why?
|
| Hospital Costs | 3 | 2016 | 117 | 0.680 |
Why?
|
| Delivery of Health Care | 7 | 2018 | 894 | 0.670 |
Why?
|
| Simvastatin | 2 | 2017 | 55 | 0.670 |
Why?
|
| Disease Management | 8 | 2020 | 593 | 0.660 |
Why?
|
| Logistic Models | 29 | 2017 | 1979 | 0.660 |
Why?
|
| Electronic Health Records | 6 | 2014 | 976 | 0.660 |
Why?
|
| Patient-Centered Care | 3 | 2018 | 493 | 0.650 |
Why?
|
| Patient Satisfaction | 8 | 2016 | 647 | 0.640 |
Why?
|
| Exercise Test | 9 | 2015 | 615 | 0.630 |
Why?
|
| Heart Diseases | 7 | 2012 | 347 | 0.620 |
Why?
|
| Myocardial Reperfusion | 9 | 2010 | 50 | 0.610 |
Why?
|
| Sickness Impact Profile | 5 | 2005 | 55 | 0.590 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 146 | 0.590 |
Why?
|
| Health Services Accessibility | 5 | 2016 | 897 | 0.590 |
Why?
|
| Cardiovascular Agents | 6 | 2016 | 152 | 0.570 |
Why?
|
| Health Status Indicators | 5 | 2009 | 169 | 0.560 |
Why?
|
| Social Media | 2 | 2019 | 139 | 0.560 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 335 | 0.550 |
Why?
|
| Cost of Illness | 5 | 2015 | 289 | 0.550 |
Why?
|
| Odds Ratio | 24 | 2017 | 1025 | 0.550 |
Why?
|
| Evidence-Based Medicine | 7 | 2018 | 718 | 0.550 |
Why?
|
| Medical Informatics | 2 | 2017 | 99 | 0.540 |
Why?
|
| Aspirin | 8 | 2016 | 378 | 0.540 |
Why?
|
| Prospective Studies | 39 | 2022 | 7079 | 0.540 |
Why?
|
| Monitoring, Physiologic | 3 | 2021 | 268 | 0.540 |
Why?
|
| Proportional Hazards Models | 18 | 2017 | 1210 | 0.530 |
Why?
|
| Search Engine | 1 | 2016 | 10 | 0.530 |
Why?
|
| Stroke | 16 | 2018 | 1067 | 0.520 |
Why?
|
| Emergency Medical Services | 4 | 2016 | 550 | 0.520 |
Why?
|
| Crowdsourcing | 1 | 2016 | 18 | 0.520 |
Why?
|
| Stents | 6 | 2014 | 504 | 0.510 |
Why?
|
| Postoperative Hemorrhage | 6 | 2021 | 86 | 0.510 |
Why?
|
| Hemorrhage | 13 | 2018 | 645 | 0.510 |
Why?
|
| Program Evaluation | 5 | 2020 | 876 | 0.510 |
Why?
|
| Coronary Restenosis | 4 | 2013 | 19 | 0.510 |
Why?
|
| Recovery of Function | 3 | 2009 | 648 | 0.500 |
Why?
|
| Comorbidity | 19 | 2019 | 1547 | 0.500 |
Why?
|
| Cell Phone | 1 | 2016 | 70 | 0.490 |
Why?
|
| Emergency Service, Hospital | 7 | 2020 | 1973 | 0.480 |
Why?
|
| Survival Rate | 19 | 2020 | 1875 | 0.460 |
Why?
|
| Patient Care Team | 3 | 2015 | 602 | 0.460 |
Why?
|
| Peer Review | 1 | 2014 | 47 | 0.460 |
Why?
|
| Incidence | 22 | 2021 | 2635 | 0.450 |
Why?
|
| Databases, Factual | 6 | 2019 | 1279 | 0.450 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 79 | 0.450 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 48 | 0.450 |
Why?
|
| Self Care | 2 | 2015 | 368 | 0.440 |
Why?
|
| Health Policy | 6 | 2017 | 353 | 0.440 |
Why?
|
| Prognosis | 22 | 2020 | 3788 | 0.440 |
Why?
|
| Patient Compliance | 8 | 2014 | 562 | 0.440 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 513 | 0.440 |
Why?
|
| Mobile Applications | 3 | 2021 | 159 | 0.420 |
Why?
|
| Surveys and Questionnaires | 25 | 2022 | 5377 | 0.420 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 736 | 0.410 |
Why?
|
| Patient Participation | 1 | 2016 | 409 | 0.400 |
Why?
|
| Decision Support Techniques | 4 | 2018 | 405 | 0.400 |
Why?
|
| Antihypertensive Agents | 6 | 2014 | 490 | 0.400 |
Why?
|
| Age Factors | 19 | 2017 | 3120 | 0.400 |
Why?
|
| Acute Disease | 12 | 2011 | 968 | 0.390 |
Why?
|
| Health Services Research | 6 | 2016 | 389 | 0.390 |
Why?
|
| Survival Analysis | 14 | 2010 | 1265 | 0.390 |
Why?
|
| Health Surveys | 3 | 2013 | 492 | 0.390 |
Why?
|
| Severity of Illness Index | 20 | 2017 | 2739 | 0.380 |
Why?
|
| Physician's Role | 1 | 2013 | 203 | 0.370 |
Why?
|
| Hypertension | 4 | 2014 | 1243 | 0.370 |
Why?
|
| Prescriptions | 2 | 2010 | 68 | 0.370 |
Why?
|
| Patient Identification Systems | 3 | 2016 | 16 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 5 | 2019 | 535 | 0.370 |
Why?
|
| Benchmarking | 4 | 2021 | 176 | 0.360 |
Why?
|
| Cardiac Output, Low | 3 | 2006 | 66 | 0.360 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2010 | 20 | 0.360 |
Why?
|
| Risk | 11 | 2019 | 856 | 0.360 |
Why?
|
| Preventive Health Services | 2 | 2015 | 145 | 0.350 |
Why?
|
| Research Design | 7 | 2016 | 1040 | 0.350 |
Why?
|
| Software | 2 | 2014 | 610 | 0.350 |
Why?
|
| Ambulatory Care | 7 | 2015 | 506 | 0.350 |
Why?
|
| Fibrinolytic Agents | 7 | 2021 | 249 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 1363 | 0.340 |
Why?
|
| Medication Adherence | 4 | 2015 | 569 | 0.340 |
Why?
|
| Patient Transfer | 3 | 2011 | 164 | 0.340 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 14 | 0.340 |
Why?
|
| Radial Artery | 4 | 2017 | 69 | 0.340 |
Why?
|
| Medicare | 10 | 2021 | 724 | 0.330 |
Why?
|
| Precision Medicine | 3 | 2018 | 384 | 0.330 |
Why?
|
| Monitoring, Ambulatory | 2 | 2024 | 84 | 0.330 |
Why?
|
| Predictive Value of Tests | 11 | 2019 | 1943 | 0.330 |
Why?
|
| Renal Dialysis | 9 | 2019 | 420 | 0.330 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 138 | 0.320 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2018 | 68 | 0.320 |
Why?
|
| Sex Factors | 9 | 2016 | 1953 | 0.310 |
Why?
|
| Coronary Stenosis | 3 | 2013 | 39 | 0.310 |
Why?
|
| Diabetes Mellitus | 6 | 2014 | 1004 | 0.310 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2009 | 34 | 0.310 |
Why?
|
| Prevalence | 17 | 2017 | 2565 | 0.310 |
Why?
|
| Health Plan Implementation | 1 | 2010 | 136 | 0.310 |
Why?
|
| Withholding Treatment | 2 | 2010 | 70 | 0.300 |
Why?
|
| Mental Disorders | 2 | 2007 | 1010 | 0.300 |
Why?
|
| Cardiology Service, Hospital | 3 | 2020 | 27 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2017 | 566 | 0.300 |
Why?
|
| Diabetic Angiopathies | 2 | 2008 | 263 | 0.290 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 98 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 283 | 0.290 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 40 | 0.290 |
Why?
|
| Depressive Disorder | 3 | 2010 | 355 | 0.290 |
Why?
|
| Syndrome | 6 | 2007 | 337 | 0.280 |
Why?
|
| Contrast Media | 3 | 2019 | 388 | 0.270 |
Why?
|
| Data Collection | 6 | 2017 | 650 | 0.270 |
Why?
|
| Regression Analysis | 8 | 2009 | 984 | 0.270 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2015 | 832 | 0.270 |
Why?
|
| Acetanilides | 1 | 2006 | 11 | 0.270 |
Why?
|
| Home Care Services | 2 | 2008 | 246 | 0.270 |
Why?
|
| Cause of Death | 8 | 2018 | 393 | 0.270 |
Why?
|
| Consensus | 3 | 2020 | 638 | 0.270 |
Why?
|
| Managed Care Programs | 1 | 2007 | 133 | 0.270 |
Why?
|
| Program Development | 3 | 2020 | 362 | 0.260 |
Why?
|
| Primary Health Care | 4 | 2018 | 1641 | 0.260 |
Why?
|
| Piperidines | 1 | 2008 | 190 | 0.260 |
Why?
|
| Heart Valve Prosthesis | 3 | 2017 | 111 | 0.260 |
Why?
|
| Anticoagulants | 4 | 2014 | 614 | 0.260 |
Why?
|
| Blood Pressure | 5 | 2014 | 1735 | 0.260 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2006 | 28 | 0.250 |
Why?
|
| Length of Stay | 6 | 2016 | 1124 | 0.250 |
Why?
|
| Physicians, Family | 1 | 2007 | 203 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 343 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 339 | 0.240 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 199 | 0.240 |
Why?
|
| Drug Therapy, Combination | 6 | 2018 | 1013 | 0.240 |
Why?
|
| Heart Valves | 1 | 2005 | 41 | 0.240 |
Why?
|
| Diabetes Complications | 1 | 2006 | 224 | 0.230 |
Why?
|
| Patient Care | 2 | 2021 | 110 | 0.230 |
Why?
|
| Adult | 28 | 2021 | 35513 | 0.230 |
Why?
|
| Selection Bias | 1 | 2004 | 37 | 0.230 |
Why?
|
| Pyrazoles | 1 | 2008 | 405 | 0.230 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 340 | 0.230 |
Why?
|
| Atherosclerosis | 2 | 2008 | 410 | 0.230 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 581 | 0.220 |
Why?
|
| Piperazines | 1 | 2006 | 337 | 0.220 |
Why?
|
| Health Care Costs | 4 | 2016 | 395 | 0.220 |
Why?
|
| Atrial Flutter | 2 | 2018 | 35 | 0.220 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 187 | 0.220 |
Why?
|
| Femoral Artery | 3 | 2017 | 174 | 0.220 |
Why?
|
| Coronary Occlusion | 2 | 2017 | 18 | 0.210 |
Why?
|
| Cooperative Behavior | 4 | 2015 | 427 | 0.210 |
Why?
|
| Electrodes, Implanted | 3 | 2013 | 106 | 0.210 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 72 | 0.210 |
Why?
|
| Exercise | 3 | 2009 | 1950 | 0.200 |
Why?
|
| Forecasting | 3 | 2021 | 358 | 0.200 |
Why?
|
| United States Food and Drug Administration | 3 | 2013 | 198 | 0.200 |
Why?
|
| Creatinine | 7 | 2019 | 475 | 0.200 |
Why?
|
| Time-to-Treatment | 2 | 2014 | 180 | 0.200 |
Why?
|
| Infection Control | 2 | 2021 | 134 | 0.200 |
Why?
|
| Postoperative Care | 2 | 2018 | 243 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2024 | 139 | 0.200 |
Why?
|
| Cardiac Rehabilitation | 2 | 2016 | 35 | 0.190 |
Why?
|
| Equipment Safety | 2 | 2013 | 39 | 0.190 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 148 | 0.190 |
Why?
|
| Palliative Care | 2 | 2009 | 721 | 0.190 |
Why?
|
| Mandatory Reporting | 2 | 2015 | 46 | 0.190 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 132 | 0.190 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2014 | 93 | 0.190 |
Why?
|
| Clinical Competence | 4 | 2017 | 1021 | 0.190 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2016 | 261 | 0.190 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2019 | 52 | 0.190 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 531 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2541 | 0.180 |
Why?
|
| Angioplasty | 2 | 2011 | 47 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 252 | 0.170 |
Why?
|
| Psychometrics | 1 | 2004 | 685 | 0.170 |
Why?
|
| Patient Admission | 2 | 2019 | 184 | 0.170 |
Why?
|
| Troponin I | 2 | 2019 | 75 | 0.170 |
Why?
|
| Health Services | 1 | 2021 | 103 | 0.170 |
Why?
|
| Off-Label Use | 2 | 2017 | 51 | 0.170 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 3033 | 0.170 |
Why?
|
| Cross-Sectional Studies | 14 | 2016 | 5070 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2002 | 227 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 169 | 0.160 |
Why?
|
| Secondary Prevention | 3 | 2014 | 220 | 0.160 |
Why?
|
| Mitral Valve | 2 | 2018 | 86 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 115 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 107 | 0.160 |
Why?
|
| Confidence Intervals | 7 | 2012 | 319 | 0.160 |
Why?
|
| Hospital Administration | 3 | 2015 | 21 | 0.160 |
Why?
|
| Decision Making | 4 | 2016 | 851 | 0.160 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2019 | 18 | 0.160 |
Why?
|
| Chest Pain | 3 | 2016 | 89 | 0.160 |
Why?
|
| Drug Utilization | 4 | 2015 | 167 | 0.160 |
Why?
|
| Prosthesis Implantation | 2 | 2010 | 144 | 0.150 |
Why?
|
| Statistics as Topic | 3 | 2016 | 304 | 0.150 |
Why?
|
| Shock, Cardiogenic | 4 | 2014 | 59 | 0.150 |
Why?
|
| Echocardiography | 4 | 2017 | 627 | 0.150 |
Why?
|
| Inpatients | 3 | 2016 | 464 | 0.150 |
Why?
|
| Mental Health | 3 | 2016 | 684 | 0.150 |
Why?
|
| Patient Care Management | 1 | 2019 | 56 | 0.150 |
Why?
|
| Japan | 4 | 2021 | 98 | 0.150 |
Why?
|
| Blood Pressure Determination | 3 | 2010 | 150 | 0.150 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2018 | 57 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2010 | 90 | 0.150 |
Why?
|
| Research Report | 2 | 2016 | 73 | 0.150 |
Why?
|
| Datasets as Topic | 2 | 2019 | 110 | 0.150 |
Why?
|
| Monte Carlo Method | 2 | 2016 | 138 | 0.150 |
Why?
|
| Markov Chains | 2 | 2016 | 116 | 0.150 |
Why?
|
| Europe | 2 | 2017 | 362 | 0.150 |
Why?
|
| Referral and Consultation | 4 | 2015 | 732 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2009 | 1210 | 0.150 |
Why?
|
| Pneumonia | 3 | 2016 | 599 | 0.150 |
Why?
|
| Elective Surgical Procedures | 3 | 2016 | 163 | 0.150 |
Why?
|
| Reimbursement, Incentive | 2 | 2008 | 36 | 0.140 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 4 | 0.140 |
Why?
|
| Smartphone | 1 | 2018 | 88 | 0.140 |
Why?
|
| Medication Errors | 2 | 2016 | 96 | 0.140 |
Why?
|
| Algorithms | 3 | 2021 | 1621 | 0.140 |
Why?
|
| American Medical Association | 2 | 2013 | 17 | 0.140 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2017 | 47 | 0.140 |
Why?
|
| Blood Transfusion | 2 | 2017 | 293 | 0.140 |
Why?
|
| Thrombosis | 3 | 2018 | 323 | 0.140 |
Why?
|
| Communication | 3 | 2016 | 840 | 0.140 |
Why?
|
| Risk Adjustment | 4 | 2013 | 79 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 1000 | 0.140 |
Why?
|
| Surgeons | 1 | 2021 | 277 | 0.130 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2016 | 22 | 0.130 |
Why?
|
| Heart Arrest | 2 | 2013 | 328 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2018 | 215 | 0.130 |
Why?
|
| Age Distribution | 5 | 2013 | 376 | 0.130 |
Why?
|
| Endarterectomy, Carotid | 2 | 2014 | 47 | 0.130 |
Why?
|
| Insurance, Health | 3 | 2013 | 271 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 864 | 0.130 |
Why?
|
| Computers | 1 | 2016 | 65 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2009 | 360 | 0.130 |
Why?
|
| International Cooperation | 1 | 2016 | 173 | 0.130 |
Why?
|
| Exercise Tolerance | 2 | 2008 | 269 | 0.130 |
Why?
|
| Deprescriptions | 1 | 2016 | 34 | 0.120 |
Why?
|
| Health Care Surveys | 5 | 2011 | 558 | 0.120 |
Why?
|
| Mobility Limitation | 1 | 2016 | 62 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 248 | 0.120 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 220 | 0.120 |
Why?
|
| Workload | 1 | 2017 | 152 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2015 | 52 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 272 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 60 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1492 | 0.120 |
Why?
|
| Saphenous Vein | 1 | 2014 | 32 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2014 | 16 | 0.110 |
Why?
|
| Vitamin K | 1 | 2014 | 40 | 0.110 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2013 | 5 | 0.110 |
Why?
|
| Andropause | 1 | 2013 | 5 | 0.110 |
Why?
|
| Chronic Disease | 6 | 2017 | 1707 | 0.110 |
Why?
|
| Pyridines | 2 | 2008 | 477 | 0.110 |
Why?
|
| Antithrombins | 1 | 2014 | 53 | 0.110 |
Why?
|
| Patient Safety | 2 | 2016 | 291 | 0.110 |
Why?
|
| Community Health Services | 2 | 2013 | 226 | 0.110 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2013 | 45 | 0.110 |
Why?
|
| Hyperkalemia | 1 | 2013 | 26 | 0.110 |
Why?
|
| Postoperative Period | 2 | 2005 | 324 | 0.110 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 147 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 45 | 0.110 |
Why?
|
| Contraindications | 4 | 2016 | 88 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 251 | 0.110 |
Why?
|
| Outpatients | 1 | 2016 | 367 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 94 | 0.100 |
Why?
|
| Gait | 1 | 2016 | 281 | 0.100 |
Why?
|
| No-Reflow Phenomenon | 1 | 2012 | 4 | 0.100 |
Why?
|
| Prosthesis Design | 1 | 2015 | 308 | 0.100 |
Why?
|
| Health Care Reform | 1 | 2014 | 99 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2014 | 158 | 0.100 |
Why?
|
| Silicones | 1 | 2012 | 23 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2013 | 109 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2013 | 359 | 0.100 |
Why?
|
| Coronary Circulation | 2 | 2012 | 137 | 0.100 |
Why?
|
| Medically Uninsured | 2 | 2013 | 127 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 2 | 2016 | 1741 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1945 | 0.090 |
Why?
|
| Biomarkers | 7 | 2019 | 3896 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 72 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2010 | 386 | 0.090 |
Why?
|
| Longitudinal Studies | 7 | 2016 | 2716 | 0.090 |
Why?
|
| Systole | 3 | 2009 | 191 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2008 | 76 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2013 | 528 | 0.090 |
Why?
|
| Clinical Medicine | 1 | 2011 | 21 | 0.090 |
Why?
|
| Documentation | 1 | 2013 | 182 | 0.090 |
Why?
|
| Heart Function Tests | 3 | 2005 | 60 | 0.090 |
Why?
|
| Asthma | 1 | 2004 | 2219 | 0.090 |
Why?
|
| Automation | 1 | 2010 | 80 | 0.090 |
Why?
|
| Warfarin | 2 | 2008 | 147 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 74 | 0.090 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 41 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 1209 | 0.080 |
Why?
|
| Kidney Diseases | 3 | 2009 | 368 | 0.080 |
Why?
|
| Heart Conduction System | 2 | 2007 | 94 | 0.080 |
Why?
|
| Testosterone | 1 | 2013 | 379 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2015 | 1084 | 0.080 |
Why?
|
| Policy | 1 | 2011 | 145 | 0.080 |
Why?
|
| Organizational Innovation | 2 | 2021 | 140 | 0.080 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 389 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 3 | 2014 | 682 | 0.080 |
Why?
|
| Enoxaparin | 1 | 2009 | 59 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2013 | 862 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 85 | 0.080 |
Why?
|
| Peptides | 2 | 2016 | 911 | 0.080 |
Why?
|
| Public Health Informatics | 1 | 2008 | 8 | 0.080 |
Why?
|
| Linear Models | 4 | 2016 | 816 | 0.080 |
Why?
|
| Research | 3 | 2008 | 410 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 254 | 0.080 |
Why?
|
| Phenotype | 1 | 2017 | 3058 | 0.080 |
Why?
|
| Colorado | 4 | 2010 | 4396 | 0.080 |
Why?
|
| State Health Plans | 1 | 2008 | 32 | 0.080 |
Why?
|
| Safety | 1 | 2010 | 329 | 0.080 |
Why?
|
| Ventricular Dysfunction | 1 | 2008 | 15 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2013 | 768 | 0.080 |
Why?
|
| Information Services | 1 | 2008 | 46 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 207 | 0.070 |
Why?
|
| Coronary Care Units | 1 | 2007 | 16 | 0.070 |
Why?
|
| Intraoperative Complications | 2 | 2012 | 132 | 0.070 |
Why?
|
| Spirituality | 1 | 2009 | 81 | 0.070 |
Why?
|
| Disease Progression | 4 | 2017 | 2613 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 134 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 1098 | 0.070 |
Why?
|
| Rehabilitation | 1 | 2007 | 16 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 1275 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2008 | 88 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 305 | 0.070 |
Why?
|
| California | 2 | 2006 | 400 | 0.070 |
Why?
|
| Personnel Turnover | 1 | 2007 | 38 | 0.070 |
Why?
|
| Tomography, X-Ray | 1 | 2006 | 4 | 0.070 |
Why?
|
| ROC Curve | 2 | 2009 | 502 | 0.070 |
Why?
|
| Societies, Nursing | 1 | 2006 | 21 | 0.070 |
Why?
|
| Ranolazine | 1 | 2006 | 25 | 0.070 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2007 | 92 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 741 | 0.070 |
Why?
|
| District of Columbia | 2 | 2018 | 26 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 80 | 0.070 |
Why?
|
| Office Visits | 1 | 2006 | 81 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2008 | 478 | 0.070 |
Why?
|
| Drug Utilization Review | 2 | 2016 | 56 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2010 | 686 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2006 | 104 | 0.060 |
Why?
|
| Hospitals, High-Volume | 2 | 2017 | 39 | 0.060 |
Why?
|
| Survivors | 1 | 2009 | 463 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 277 | 0.060 |
Why?
|
| Michigan | 2 | 2019 | 103 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 197 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2007 | 200 | 0.060 |
Why?
|
| Sirolimus | 1 | 2006 | 189 | 0.060 |
Why?
|
| Physical Endurance | 1 | 2006 | 269 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2007 | 1271 | 0.060 |
Why?
|
| Propensity Score | 2 | 2021 | 265 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2005 | 99 | 0.060 |
Why?
|
| Animals | 2 | 2018 | 34600 | 0.060 |
Why?
|
| Refusal to Participate | 1 | 2004 | 6 | 0.060 |
Why?
|
| Symptom Assessment | 2 | 2016 | 127 | 0.060 |
Why?
|
| Troponin T | 2 | 2019 | 57 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2017 | 220 | 0.060 |
Why?
|
| Medicaid | 1 | 2008 | 437 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2015 | 2266 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 2006 | 195 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 261 | 0.050 |
Why?
|
| Diastole | 1 | 2004 | 151 | 0.050 |
Why?
|
| Life Style | 1 | 2006 | 460 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 369 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 308 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2003 | 69 | 0.050 |
Why?
|
| Drug Labeling | 2 | 2016 | 40 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2008 | 647 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2016 | 3342 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2002 | 116 | 0.050 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 29 | 0.050 |
Why?
|
| Adolescent | 2 | 2013 | 20302 | 0.050 |
Why?
|
| Utah | 1 | 2021 | 65 | 0.050 |
Why?
|
| Pediatrics | 1 | 2009 | 1062 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 291 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 767 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 10451 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 58 | 0.040 |
Why?
|
| Health Behavior | 2 | 2003 | 741 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 86 | 0.040 |
Why?
|
| Insurance Coverage | 2 | 2014 | 222 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 109 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2016 | 717 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 67 | 0.040 |
Why?
|
| Obesity | 2 | 2015 | 2863 | 0.040 |
Why?
|
| Self-Management | 1 | 2021 | 161 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2019 | 42 | 0.040 |
Why?
|
| Fee-for-Service Plans | 2 | 2009 | 88 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 92 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2014 | 759 | 0.040 |
Why?
|
| Databases as Topic | 2 | 2009 | 62 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2008 | 101 | 0.040 |
Why?
|
| Alcoholism | 1 | 2004 | 766 | 0.040 |
Why?
|
| Life Tables | 2 | 2009 | 18 | 0.040 |
Why?
|
| Child | 3 | 2013 | 20806 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 2018 | 33 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 780 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2013 | 590 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2018 | 61 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 40 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 22 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 84 | 0.030 |
Why?
|
| Neoplasms | 2 | 2009 | 2475 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2017 | 41 | 0.030 |
Why?
|
| Coronary Thrombosis | 1 | 2016 | 23 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 19 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 828 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 136 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 582 | 0.030 |
Why?
|
| Hypesthesia | 1 | 2016 | 16 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 99 | 0.030 |
Why?
|
| Transportation | 1 | 2016 | 50 | 0.030 |
Why?
|
| Public Health | 2 | 2013 | 486 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 70 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1417 | 0.030 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 122 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2016 | 121 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 2014 | 24 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 3383 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 84 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 2014 | 39 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 372 | 0.030 |
Why?
|
| Dabigatran | 1 | 2014 | 21 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 82 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 206 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 134 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 61 | 0.030 |
Why?
|
| San Francisco | 2 | 2004 | 52 | 0.030 |
Why?
|
| Small-Area Analysis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Medical Assistance | 1 | 2013 | 12 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2010 | 1567 | 0.030 |
Why?
|
| Metals | 1 | 2014 | 127 | 0.030 |
Why?
|
| Societies | 1 | 2013 | 36 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 138 | 0.030 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2013 | 16 | 0.030 |
Why?
|
| Administrative Personnel | 1 | 2013 | 28 | 0.030 |
Why?
|
| Medical Audit | 1 | 2012 | 77 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2015 | 256 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 151 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 122 | 0.020 |
Why?
|
| Nitrates | 1 | 2011 | 87 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 190 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 865 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 23 | 0.020 |
Why?
|
| Feedback | 1 | 2011 | 159 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 505 | 0.020 |
Why?
|
| Hirudins | 1 | 2010 | 48 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 99 | 0.020 |
Why?
|
| Hospitals, Private | 1 | 2009 | 12 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 724 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 70 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1359 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2013 | 558 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 1231 | 0.020 |
Why?
|
| Pressure | 1 | 2010 | 240 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2010 | 74 | 0.020 |
Why?
|
| Leadership | 1 | 2013 | 357 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2008 | 27 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 376 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 37 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2008 | 21 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2008 | 21 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 93 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 94 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2008 | 115 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 213 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2007 | 21 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 72 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2007 | 4 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 51 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 1308 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 190 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1284 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2006 | 953 | 0.020 |
Why?
|
| Health Personnel | 1 | 2013 | 649 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2006 | 39 | 0.020 |
Why?
|
| Reperfusion | 1 | 2006 | 35 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 285 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 348 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 347 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2007 | 137 | 0.020 |
Why?
|
| Anemia | 1 | 2007 | 161 | 0.020 |
Why?
|
| Drug Implants | 1 | 2006 | 82 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2006 | 89 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2008 | 236 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 150 | 0.020 |
Why?
|
| Training Support | 1 | 2005 | 28 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2006 | 226 | 0.020 |
Why?
|
| Attitude | 1 | 2007 | 250 | 0.010 |
Why?
|
| Patients | 1 | 2006 | 166 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 221 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 125 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2005 | 103 | 0.010 |
Why?
|
| Recurrence | 1 | 2007 | 1003 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 656 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 758 | 0.010 |
Why?
|
| Echocardiography, Stress | 1 | 2003 | 20 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2003 | 16 | 0.010 |
Why?
|
| Dementia | 1 | 2006 | 227 | 0.010 |
Why?
|
| Social Support | 1 | 2007 | 587 | 0.010 |
Why?
|
| Washington | 1 | 2002 | 148 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2005 | 428 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1825 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2007 | 723 | 0.010 |
Why?
|
| Reoperation | 1 | 2003 | 560 | 0.010 |
Why?
|
| Urban Population | 1 | 2002 | 444 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 5739 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 1217 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 8993 | 0.010 |
Why?
|